These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 34769210)

  • 21. Synthesis and Identification of Novel Potential Molecules Against COVID-19 Main Protease Through Structure-Guided Virtual Screening Approach.
    El Bakri Y; Anouar EH; Ahmad S; Nassar AA; Taha ML; Mague JT; El Ghayati L; Essassi EM
    Appl Biochem Biotechnol; 2021 Nov; 193(11):3602-3623. PubMed ID: 34324152
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Design, synthesis and biological evaluation of novel 3C-like protease inhibitors as lead compounds against SARS-CoV-2.
    Yan Y; Liu H; Wu D; Gu Z; Guo W; Yao H; Lin K; Li X
    Future Med Chem; 2024; 16(9):887-903. PubMed ID: 38618977
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Docking-based virtual screening studies aiming at the covalent inhibition of SARS-CoV-2 M
    Soulère L; Barbier T; Queneau Y
    Comput Biol Chem; 2021 Jun; 92():107463. PubMed ID: 33677227
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Interaction of small molecules with the SARS-CoV-2 papain-like protease: In silico studies and in vitro validation of protease activity inhibition using an enzymatic inhibition assay.
    Pitsillou E; Liang J; Ververis K; Hung A; Karagiannis TC
    J Mol Graph Model; 2021 May; 104():107851. PubMed ID: 33556646
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Molecular docking, binding mode analysis, molecular dynamics, and prediction of ADMET/toxicity properties of selective potential antiviral agents against SARS-CoV-2 main protease: an effort toward drug repurposing to combat COVID-19.
    Rai H; Barik A; Singh YP; Suresh A; Singh L; Singh G; Nayak UY; Dubey VK; Modi G
    Mol Divers; 2021 Aug; 25(3):1905-1927. PubMed ID: 33582935
    [TBL] [Abstract][Full Text] [Related]  

  • 26. 3-chymotrypsin-like protease in SARS-CoV-2.
    Al Adem K; Ferreira JC; Villanueva AJ; Fadl S; El-Sadaany F; Masmoudi I; Gidiya Y; Gurudza T; Cardoso THS; Saksena NK; Rabeh WM
    Biosci Rep; 2024 Aug; 44(8):. PubMed ID: 39036877
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dual inhibition of SARS-CoV-2 and human rhinovirus with protease inhibitors in clinical development.
    Liu C; Boland S; Scholle MD; Bardiot D; Marchand A; Chaltin P; Blatt LM; Beigelman L; Symons JA; Raboisson P; Gurard-Levin ZA; Vandyck K; Deval J
    Antiviral Res; 2021 Mar; 187():105020. PubMed ID: 33515606
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reconstruction of the unbinding pathways of noncovalent SARS-CoV and SARS-CoV-2 3CLpro inhibitors using unbiased molecular dynamics simulations.
    Noroozi Tiyoula F; Aryapour H
    PLoS One; 2022; 17(2):e0263251. PubMed ID: 35139108
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In Silico Identification of Potential Natural Product Inhibitors of Human Proteases Key to SARS-CoV-2 Infection.
    Vivek-Ananth RP; Rana A; Rajan N; Biswal HS; Samal A
    Molecules; 2020 Aug; 25(17):. PubMed ID: 32842606
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Glycyrrhizic acid conjugates with amino acid methyl esters target the main protease, exhibiting antiviral activity against wild-type and nirmatrelvir-resistant SARS-CoV-2 variants.
    Le UNP; Chang YJ; Lu CH; Chen Y; Su WC; Chao ST; Baltina LA; Petrova SF; Li SR; Hung MC; Lai MMC; Baltina LA; Lin CW
    Antiviral Res; 2024 Jul; 227():105920. PubMed ID: 38821317
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In silico analysis and identification of antiviral coumarin derivatives against 3-chymotrypsin-like main protease of the novel coronavirus SARS-CoV-2.
    Abdizadeh R; Hadizadeh F; Abdizadeh T
    Mol Divers; 2022 Apr; 26(2):1053-1076. PubMed ID: 34213728
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Computational Simulation of HIV Protease Inhibitors to the Main Protease (Mpro) of SARS-CoV-2: Implications for COVID-19 Drugs Design.
    Yu W; Wu X; Zhao Y; Chen C; Yang Z; Zhang X; Ren J; Wang Y; Wu C; Li C; Chen R; Wang X; Zheng W; Liao H; Yuan X
    Molecules; 2021 Dec; 26(23):. PubMed ID: 34885967
    [TBL] [Abstract][Full Text] [Related]  

  • 33. MPI8 is Potent against SARS-CoV-2 by Inhibiting Dually and Selectively the SARS-CoV-2 Main Protease and the Host Cathepsin L.
    Ma XR; Alugubelli YR; Ma Y; Vatansever EC; Scott DA; Qiao Y; Yu G; Xu S; Liu WR
    ChemMedChem; 2022 Jan; 17(1):e202100456. PubMed ID: 34242492
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Statine-based peptidomimetic compounds as inhibitors for SARS-CoV-2 main protease (SARS-CoV‑2 Mpro).
    Azevedo PHRA; Camargo PG; Constant LEC; Costa SDS; Silva CS; Rosa AS; Souza DDC; Tucci AR; Ferreira VNS; Oliveira TKF; Borba NRR; Rodrigues CR; Albuquerque MG; Dias LRS; Garrett R; Miranda MD; Allonso D; Lima CHDS; Muri EMF
    Sci Rep; 2024 Apr; 14(1):8991. PubMed ID: 38637583
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In-silico guided design, screening, and molecular dynamic simulation studies for the identification of potential SARS-CoV-2 main protease inhibitors for the targeted treatment of COVID-19.
    Gutti G; He Y; Coldren WH; Lalisse RF; Border SE; Hadad CM; McElroy CA; Ekici ÖD
    J Biomol Struct Dyn; 2024; 42(4):1733-1750. PubMed ID: 37114441
    [TBL] [Abstract][Full Text] [Related]  

  • 36. SARS-CoV-2 Main Protease Active Site Ligands in the Human Metabolome.
    Sardanelli AM; Isgrò C; Palese LL
    Molecules; 2021 Mar; 26(5):. PubMed ID: 33807773
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Active Learning and the Potential of Neural Networks Accelerate Molecular Screening for the Design of a New Molecule Effective against SARS-CoV-2.
    Yassine R; Makrem M; Farhat F
    Biomed Res Int; 2021; 2021():6696012. PubMed ID: 34124259
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Structure-Based Virtual Screening to Discover Potential Lead Molecules for the SARS-CoV-2 Main Protease.
    Gahlawat A; Kumar N; Kumar R; Sandhu H; Singh IP; Singh S; Sjöstedt A; Garg P
    J Chem Inf Model; 2020 Dec; 60(12):5781-5793. PubMed ID: 32687345
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Protease targeted COVID-19 drug discovery and its challenges: Insight into viral main protease (Mpro) and papain-like protease (PLpro) inhibitors.
    Amin SA; Banerjee S; Ghosh K; Gayen S; Jha T
    Bioorg Med Chem; 2021 Jan; 29():115860. PubMed ID: 33191083
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In silico evaluation of Philippine Natural Products against SARS-CoV-2 Main Protease.
    Cheng AJT; Macalino SJY; Billones JB; Balolong MP; Murao LAE; Carrillo MCO
    J Mol Model; 2022 Oct; 28(11):345. PubMed ID: 36205801
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.